Romiplostim N01 in the Treatment of Refractory Chemoradiotherapy-induced AA

Summary

This study aimed to explore the efficacy and safety of romiplostim N01 in the treatment of relapsed/refractory chemoradiotherapy-induced aplastic anemia

Timeline

Start

2026-06

Primary completion

2028-12

Completion

2029-12

Outcome

Outcome not reported

Stopped: “The registration of this research plan was incorrect. A new registration has been done.”

Drugs

Indications